Throop firefighters selling chicken dinners on Big Game Day
Throop Hose Company #1 was busy making and selling chicken dinners.
Volunteers packed up the dinners to go drive-thru style.
Scranton bars, restaurants ready for Big Game Sunday
All of the proceeds benefit Throop Hose Company #1.
'Well, it's important for the company, it's important for the community, not only ours, but for our neighboring company. The money goes right back into maintaining better equipment to help protect the people of the town and their properties,' said Throop Hose Company #1 President Dave Benson.
Throop Hose Company #1 also hopes to bring people to their company to interest them in becoming a volunteer firefighter.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
3 Crypto-Centric Stocks to Grab Before the Next Bitcoin Rally
The cryptocurrency market has been giving up gains lately, with Bitcoin (BTC) pulling back sharply after hitting a new all-time high last week. Several macro concerns, including uncertainty over a rate cut in September, have been denting investors' sentiment. However, the decline is temporary, and the cryptocurrency is poised to resume its northbound journey, given that it has already had a great year so far and a rate cut in the coming months is expected to give it a further push. It would thus be an ideal time to invest in crypto-focused stocks. We have selected three stocks, namely PayPal Holdings PYPL, Interactive Brokers Group IBKR and Robinhood Markets, Inc. HOOD. Each of these stocks has strong growth potential for 2025 and has seen positive earnings estimate revisions in the past 90 days. Bitcoin Retreats But Has More Room to Grow Bitcoin has declined 5% over the past week and was trading at $113,772.65 on Wednesday morning after hitting an all-time high of $124.496, its fourth record high this year. The high came following the release of the consumer price index (CPI) report. CPI for July rose less than expected, raising hopes that the Federal Reserve would go for a rate cut in September. However, the euphoria was short-lived after higher-than-expected wholesale inflation data raised fresh doubts over a September rate cut. Investor sentiment was further dented after Treasury Secretary Scott Bessent said last week that President Donald Trump's strategic bitcoin reserve, which was created in March, would only consist of bitcoin seized by the federal government, while officials look into 'budget-neutral pathways to acquire more Bitcoin.' However, experts believe that the decline in Bitcoin is temporary and once these macro concerns ease, the cryptocurrency will resume its rally. Although the Federal Reserve hasn't suggested any timeline for the next rate cut, markets are pricing in an 85% chance of a 25-basis-point rate cut in September, according to the CME FedWatch Tool. 3 Bitcoin-Centric Stocks With Upside PayPal Holdings PayPal Holdings provides digital wallet services that enable users to purchase, transfer and sell various cryptocurrencies, such as Bitcoin, Ethereum, Bitcoin Cash and Litecoin. Through PYPL, users can use cryptocurrencies to pay for goods and services from online merchants. Additionally, PayPal's mobile wallet platform, Venmo, allows users to engage in cryptocurrency buying and selling activities. PayPal Holdings' expected earnings growth rate for the current year is 10.8%.The Zacks Consensus Estimate for current-year earnings has improved 2.6% over the last 60 days. PYPL currently has a Zacks Rank #2 (Buy). Robinhood Markets Robinhood Markets, Inc. operates a financial services platform in the United States. Its platform allows users to invest in stocks, exchange-traded funds, options, gold and cryptocurrencies. HOOD buys and sells Bitcoin, Ethereum, Dogecoin and other cryptocurrencies using its Robinhood Crypto platform. Robinhood Markets' expected earnings growth rate for the current year is 39.5%.The Zacks Consensus Estimate for current-year earnings has improved 23.6% over the past 60 days. HOOD currently has a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Interactive Brokers Group, Inc. Interactive Brokers Group is a global automated electronic broker. IBKR executes, processes and trades in cryptocurrencies. IBKR's commodities futures trading desk also offers customers a chance to trade cryptocurrency futures. Interactive Brokers Group has an expected earnings growth rate of 11.4% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 11.4% over the last 60 days. IBKR currently has a Zacks Rank #1. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Interactive Brokers Group, Inc. (IBKR) : Free Stock Analysis Report PayPal Holdings, Inc. (PYPL) : Free Stock Analysis Report Robinhood Markets, Inc. (HOOD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Inicia sesión para acceder a tu portafolio
Yahoo
17 minutes ago
- Yahoo
DexCom Expands Access and Innovation While Balancing Headwinds
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research Short-Term Growth Drivers U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management's confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom's over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom's competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Long-Term Growth Drivers Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM's clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom's G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom's innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a 'consumer technology mindset,' rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Challenges Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom's business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Competition Update Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % — beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche's potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic's Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic's MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Conclusion DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company's leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
18 minutes ago
- Yahoo
Analog Devices Q3 Earnings Beat Estimates, Revenues Rise Y/Y
Analog Devices ADI reported third-quarter fiscal 2025 non-GAAP earnings of $2.05 per share, which beat the Zacks Consensus Estimate by 6.2%. This company reported earnings of $1.58 per share in the year-ago period. Analog Devices' earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 5.6%. Analog Devices' second-quarter fiscal 2025 revenues of $2.88 billion beat the Zacks Consensus Estimate by 4.45%. The top line increased from the year-ago quarter's $2.31 billion. Analog Devices, Inc. Price, Consensus and EPS Surprise Analog Devices, Inc. price-consensus-eps-surprise-chart | Analog Devices, Inc. Quote Analog Devices' Q3 Details Industrial: Revenues from this segment were $1.29 billion, representing 45% of total revenues and reflecting 23% year-over-year growth. Automotive: Revenues reached $850.6 million (or 30% of total revenue), up 22% year over year. Consumer: The segment generated $372.2 million (or 13% of revenue), marking a 21% increase compared to the same quarter last year. Communications: Revenues came in at $372.5 million, accounting for 13% of total revenues and rising 40% year over year. The adjusted gross margin expanded 130 basis points to 69.2%, while the adjusted operating margin was 42.2%, up 100 basis points year over year. ADI's Balance Sheet and Cash Flows As of Aug. 2, 2025, cash and cash equivalents were $2.32 billion, down from $2.38 billion as of May 3, 2025. The company also held $1.15 billion in short-term investments during the third quarter. Long-term debt was $8.14 billion compared with $6.65 billion at the end of the previous quarter. Analog Devices generated $1.17 billion in operating cash flow and $1.09 billion in free cash flow during the third quarter of fiscal 2025. The company returned $1.57 billion to shareholders, comprising $490 million in dividends and $1.08 billion in share repurchases. ADI Releases Q4 Guidance For the fourth quarter of fiscal 2025, management expects revenues of $3.0 billion (+/- $100 million). The Zacks Consensus Estimate for the same is pegged at $2.79 billion, indicating year-over-year growth of 14%. The company projects a reported operating margin of approximately 30.5% (+/-150 bps) and an adjusted operating margin of about 43.5% (+/-100 bps). Reported earnings are anticipated to be $1.53 (+/-$0.10) per share, while adjusted earnings are expected to be $2.22 (+/-$0.10) per share. The consensus mark for the same is pinned at $1.98 per share. Zacks Rank & Other Stocks to Consider Currently, ADI carries a Zacks Rank #2 (Buy). Amphenol APH, Qualys QLYS and F5 FFIV are some other top-ranked stocks that investors can consider in the broader Zacks Computer & Technology sector. Amphenol, Qualys and F5 sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today's Zacks #1 Rank stocks here. Amphenol shares have gained 58.4%, year to date. The Zacks Consensus Estimate for Amphenol's full-year 2025 earnings is pegged at $3.02 per share, up by 4 cents over the past seven days, suggesting a growth of 59.8% from the year-ago quarter's reported figure. Qualys shares have declined 5%, year to date. The Zacks Consensus Estimate for Qualys's full-year 2025 earnings has been revised upward to $6.35 in the past 30 days, suggesting year-over-year growth of 3.6%. F5 shares have gained 25.4%, year to date. The Zacks Consensus Estimate for F5's full-year fiscal 2025 earnings is pegged at $15.38 per share, implying a rise of 15% from the year-ago quarter's levels. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Analog Devices, Inc. (ADI) : Free Stock Analysis Report Amphenol Corporation (APH) : Free Stock Analysis Report F5, Inc. (FFIV) : Free Stock Analysis Report Qualys, Inc. (QLYS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
